FOXO3 and cancer: Moreover, restoring or stabilizing the transcriptional–electrical program pharmacologically (e.g., through SKCa/IKCa activators or FOXO3-inducing agents) may offer therapeutic potential in cardiovascular disease, cancer, or tissue repair.